• Je něco špatně v tomto záznamu ?

Validation of Babesia proteasome as a drug target

M. Jalovecka, D. Hartmann, Y. Miyamoto, L. Eckmann, O. Hajdusek, AJ. O'Donoghue, D. Sojka,

. 2018 ; 8 (3) : 394-402. [pub] 20180807

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012468

Babesiosis is a tick-transmitted zoonosis caused by apicomplexan parasites of the genus Babesia. Treatment of this emerging malaria-related disease has relied on antimalarial drugs and antibiotics. The proteasome of Plasmodium, the causative agent of malaria, has recently been validated as a target for anti-malarial drug development and therefore, in this study, we investigated the effect of epoxyketone (carfilzomib, ONX-0914 and epoxomicin) and boronic acid (bortezomib and ixazomib) proteasome inhibitors on the growth and survival of Babesia. Testing the compounds against Babesia divergens ex vivo revealed suppressive effects on parasite growth with activity that was higher than the cytotoxic effects on a non-transformed mouse macrophage cell line. Furthermore, we showed that the most-effective compound, carfilzomib, significantly reduces parasite multiplication in a Babesia microti infected mouse model without noticeable adverse effects. In addition, treatment with carfilzomib lead to an ex vivo and in vivo decrease in proteasome activity and accumulation of polyubiquitinated proteins compared to untreated control. Overall, our results demonstrate that the Babesia proteasome is a valid target for drug development and warrants the design of potent and selective B. divergens proteasome inhibitors for the treatment of babesiosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012468
003      
CZ-PrNML
005      
20190412094445.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpddr.2018.08.001 $2 doi
035    __
$a (PubMed)30103207
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jalovecka, Marie $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-370 05, Ceske Budejovice, Czech Republic; Faculty of Science, University of South Bohemia, CZ-370 05, Ceske Budejovice, Czech Republic.
245    10
$a Validation of Babesia proteasome as a drug target / $c M. Jalovecka, D. Hartmann, Y. Miyamoto, L. Eckmann, O. Hajdusek, AJ. O'Donoghue, D. Sojka,
520    9_
$a Babesiosis is a tick-transmitted zoonosis caused by apicomplexan parasites of the genus Babesia. Treatment of this emerging malaria-related disease has relied on antimalarial drugs and antibiotics. The proteasome of Plasmodium, the causative agent of malaria, has recently been validated as a target for anti-malarial drug development and therefore, in this study, we investigated the effect of epoxyketone (carfilzomib, ONX-0914 and epoxomicin) and boronic acid (bortezomib and ixazomib) proteasome inhibitors on the growth and survival of Babesia. Testing the compounds against Babesia divergens ex vivo revealed suppressive effects on parasite growth with activity that was higher than the cytotoxic effects on a non-transformed mouse macrophage cell line. Furthermore, we showed that the most-effective compound, carfilzomib, significantly reduces parasite multiplication in a Babesia microti infected mouse model without noticeable adverse effects. In addition, treatment with carfilzomib lead to an ex vivo and in vivo decrease in proteasome activity and accumulation of polyubiquitinated proteins compared to untreated control. Overall, our results demonstrate that the Babesia proteasome is a valid target for drug development and warrants the design of potent and selective B. divergens proteasome inhibitors for the treatment of babesiosis.
650    _2
$a zvířata $7 D000818
650    _2
$a Babesia $x účinky léků $x genetika $x růst a vývoj $7 D001403
650    _2
$a Babesia microti $x účinky léků $x genetika $x růst a vývoj $7 D041001
650    _2
$a babezióza $x farmakoterapie $7 D001404
650    _2
$a kyseliny boronové $x farmakologie $7 D001897
650    _2
$a buněčné linie $7 D002460
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a lékové transportní systémy $7 D016503
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a makrofágy $x účinky léků $x parazitologie $7 D008264
650    _2
$a myši $7 D051379
650    _2
$a oligopeptidy $x farmakologie $7 D009842
650    _2
$a proteasomový endopeptidasový komplex $x účinky léků $7 D046988
650    _2
$a inhibitory proteasomu $x aplikace a dávkování $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D061988
650    _2
$a proteom $x účinky léků $x genetika $7 D020543
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a validační studie $7 D023361
700    1_
$a Hartmann, David $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-370 05, Ceske Budejovice, Czech Republic; Faculty of Science, University of South Bohemia, CZ-370 05, Ceske Budejovice, Czech Republic.
700    1_
$a Miyamoto, Yukiko $u Department of Medicine, University of California, San Diego, La Jolla, USA.
700    1_
$a Eckmann, Lars $u Department of Medicine, University of California, San Diego, La Jolla, USA.
700    1_
$a Hajdusek, Ondrej $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-370 05, Ceske Budejovice, Czech Republic.
700    1_
$a O'Donoghue, Anthony J $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, USA. Electronic address: ajodonoghue@ucsd.edu.
700    1_
$a Sojka, Daniel $u Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-370 05, Ceske Budejovice, Czech Republic. Electronic address: sojkadan@gmail.com.
773    0_
$w MED00184051 $t International journal for parasitology. Drugs and drug resistance $x 2211-3207 $g Roč. 8, č. 3 (2018), s. 394-402
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30103207 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412094504 $b ABA008
999    __
$a ok $b bmc $g 1391778 $s 1050773
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c 3 $d 394-402 $e 20180807 $i 2211-3207 $m International journal for parasitology. Drugs and drug resistance $n Int J Parasitol Drugs Drug Resist $x MED00184051
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace